Antiphospholipid Antibody Syndrome: Management Issues for the Hematologist
|
|
- Stephanie Lambert
- 6 years ago
- Views:
Transcription
1 Antiphospholipid Antibody Syndrome: Management Issues for the Hematologist Wisconsin Institute of Discovery Karen Rossi/Bristol-Myers Squibb Morey A. Blinder, MD Washington University, St. Louis, MO March 9, 2018
2 Disclosure: Morey A. Blinder, M.D. Dr. Blinder has received honoraria for speaking from Janssen.
3 Antiphospholipid Antibodies (APA) Functional test ACA IgM, IgG Criteria LA β 2 GPI IgM, IgG Non-criteria ACA-IgA Anti-prothrombin ab Other APA (e.g. phosphotidyl serime) Level of APA Antibody tests (ELISA)
4 Case 1 A 42 year old man in good health presented with LE petechiae 1 year ago, was found to have a platelet count of 9,000/µl and was diagnosed with ITP. He was treated with dexamethasone and IVIG. One month later his platelet count was 157,000/µl. After a 6 hour car ride he developed a (R)LE DVT. Platelet count was 29,000/µl. Lupus anticoagulant was positive and anti-cardiolipin and b 2 GPI antibodies were present.
5 Case 1 - Questions How common are APA in ITP? What is the risk of thrombosis in APAassociated ITP? Should the patient with APA-associated ITP be treated differently than patients with primary ITP?
6 Stasi R et al. Blood 1994; 84: Diz-Kucukkaya et al. Blood 2001; 98: Prevalence of APA-associated ITP At diagnosis Stasi R et al. Blood 1994 Platelet count <50,000 Diz-Kucukkaya et al. Blood 2001 Platelet count <100,000 No. pts ACA 9 11 Lupus anticoagulant 17 8 LA + ACA Overall prevalence 39/78 (50%) 31/82 (38%) No difference in: Gender Age Initial platelet count Severity of hemorrhage
7 Response to initial therapy of ITP Response to steroids and IVIG are similar Presence of APA does not predict treatment outcome Treatment with prednisone ± IVIG APL-positive (N=20) APL-negative (n=50) p value Transient response (<3 mo) Sustained response ( 3 mo) Time to respond 9/17 (53%) 26/47 (55%) 8/17 (47%) 21/47 (45%) 0.41 Pred +IVIG 2.3 (1-12) 2.9 (1-15) 0.72 Pred 7.3 (2-26) 5.9 (1-34) 0.50 Yang Y. et al. Kor J Intern Med 2011; 26:
8 Is ITP a thrombophilic disorder? Reference n Follow up (mo) Sapatwari et al. (2000) Enge et al. (2000) Severinsen et al. (2010) Incidence x 100 person-years Patients Controls RR P ( ) ( ) ( ) <0.05 <0.05 <0.05 Noorgard et al. (2015) <0.05 Rodeghiero F. Am J. Hematol 2016; 91:39-45
9 Risk of Thrombosis in Patients with APA-associated ITP 10 studies have assessed risk of thrombosis in patients with ITP and APA (LA, ACA or anti-b 2 GPI) Including arterial and venous events LA positive LA negative OR (95% CI) Total 38/242 41/ ( ) ACA-positive ACA-negative OR (95% CI) Total 23/156 27/ ( ) Moulis G et al. Autoimmunity Rev :
10 Presence of lupus anticoagulant is strongly associated with thrombotic events in ITP Lupus anticoagulant Cumulative thrombosis-free survival Cumulative thrombosis-free survival Time (months) Time (months) Diz-Kucukkaya R et al. Blood 2001; 98:
11 Thrombotic risk of TPO-RA in ITP Number of patients with TEEs Romiplostim Eltrombopag APA-ITP ITP controls 39/653 (5.9%) 19/302 (6.3%) Arterial Venous TEE per 100 pt.-yrs Arterial 2.8 ~1.0 ~0.9 Venous Rodeghiero F. Am J. Hematol 2016; 91:39-45
12 Treatment of APA-ITP with Thrombopoietin receptor agonists ITP with triple-positive APA (LA, ACA, b 2 GPI) 2 patients with romiplostim: Patient 1 - Digital thrombosis, stroke and transaminitis Patient 2 - Digital ischemia in feet, thrombosis of thoracic aorta Thrombosis occurred at 4 and 11 weeks of therapy Platelet counts at time of thrombosis were 156,000/µl and 111,000/µl LaMoreaux B. et al. Sem Arth Rheum 2016; 45:10-12
13 Case 2 A 41 year old woman was diagnosed with an (L)LE DVT about 4 months ago after presenting with swelling. Work up demonstrated a lupus anticoagulant and an ACL. She is treated with warfarin. She has had no further thrombotic events but her INR fluctuates so that frequent testing is done and the TTR is ~40%. She is consulting regarding recommendations for further approaches to therapy.
14 Case 2 - Questions What is the risk of a thrombotic event in patients with APA and should patients receive any thromboprophylaxis? What is the risk of a second thromboembolic event? How long should a patient with APA-associated thrombosis be treated? What is the role for DOACs?
15 Risk of thrombosis with APAS: Related to APA profile 1 positive APA test ACA or β 2 GPI alone no increase in thrombotic risk LA Possible increase in thrombotic risk 2 positive APA tests LA + β 2 GPI increased thrombosis risk [OR ~4x] LA + ACA + β 2 GPI - strongly associated with thrombosis [OR 5-33x] Additional risk factors inherited thrombophilia, pregnancy, immobilization, surgery SLE often associated with APA; increased risk Lim W. ASH Education Book 2013
16 Primary Thromboprophylaxis: Aspirin therapy APLASA Trial Multicenter, randomized, double-blind, placebo controlled trial with asymptomatic, persistently positive APA individuals Median follow up 28 mo. 98 patients enrolled, randomized to receive ASA 81 mg (n=48) or placebo (n=50) Study terminated early due to unexpectedly low rate of thrombosis (3/98, all in ASA group) Erkan D et al. Arthritis and Rheumatism 2007; 56:
17 APS: Hydroxychloroquine q Hydroxychloroquine qin patients with SLE, reduced risk of initial arterial and venous thrombotic events ( APA) Study Study design Thrombosis studies But no current data to support use in patients without autoimmune disease Outcomes Wallace et al (1987) Retrospective (n-92) Arterial/venous P<0.05 Petri et al. (1994) Prospective (n=393) Arterial OR 0.36 Ruiz-Irastorza et al. (2008) Prospective cohort (n=232) Arterial/venous HR 0.26 Tekionidou et al. (2009) Jung et al. (2010) Curr Rheumatol Rep 2011; 13:77-80 Case-control (cases 144; controls 144) Case-control Cases 54; controls 108) Arterial/venous HR 0.99 Arterial/venous OR 0.32 q Role in APA patients without SLE is not defined
18 APS: Statins q Statins: possible role as anti-inflammatory, immunomodulatory agent q Retrospective study of 152 newly diagnosed SLE patients q80 patients had APA/LA qstatin use was up to clinician q1/15 (6.7%) pts. with thrombosis was on statin q22/65 (33.8%) of pts. without thrombosis were on statin qmedian follow up 69 months q Role in APA patients without SLE is not defined Watanabe T. et al. Lupus 2018; 27:
19 The How I Treat Approach 1. Establish the diagnosis 1. Patient has positive APA without prior thrombosis or pregnancy morbidity 2. Confirm that patient has persistent APA 2. Factors to consider 1. Consider primary prophylaxis only if patient has other risk factors (e.g. cardiovascular risk) 2. Consider hydroxychloroquine statin if patient has SLE 3. Consider short-term anticoagulation during high risk situations (e.g. post-operative) 4. Limit other reversible risk factors (e.g. estrogens, smoking) Chaturvedi S and McCrae KR. ASH Education Program. Hematology 2015
20 Treatment of Initial Venous Thromboembolism (VTE) Legacy therapy: Anticoagulation with UFH or LMWH with transition to VKA is standard treatment for first VTE Effect on laboratory testing: LA may elevate baseline PTT (Anti-Xa Activity) LA may interfere with INR (Vitamin K dependent factors 15-25% is therapeutic
21 Crowther M. NEJM 2003, Finazzi J Thromb Haemost 2005 Treatment of Initial VTE: Warfarin Intensity Two RCT evaluated standard intensity (INR 2-3) versus high intensity (INR 3-4) anticoagulation with warfarin in patients with APS No difference in rates of recurrent thrombosis or major bleeding
22 Risk of Recurrent VTE with APA Meta-analysis relative risk for recurrent VTE after stopping anticoagulant Quality of evidence pertaining to the risk of recurrent thrombosis among patients with APA is low Garcia D, et al. Blood 2013;122:
23 Direct Oral Anticoagulants (DOACs) in APS: Venous thromboembolism u RAPS trial v Rivaroxaban vs. warfarin for APS (RAPS) trial v With or without SLE u Methods: v Patients received standard warfarin therapy for 3 months v Randomized, controlled open-label phase 2/3 non-inferiority trial v Laboratory endpoints over 6 wks. v No thrombotic events over 6 months Cohen H. et al. Lancet 2016;122:
24 RAPS Study Results Endogenous thrombin potential Baseline Day 42 ETP for rivaroxaban was higher than warfarin and did not meet the non-inferiority threshold (set at <20% difference from warfarin) Peak thrombin generation But the peak thrombin generation is not different between rivaroxaban and warfarin Cohen H. et al. Lancet 2016;122:
25 Direct Oral Anticoagulants (DOACs) in APS: Venous thromboembolism u TRAPS (Rivaroxaban for Thrombotic Antiphospholipid syndrome) v Rivaroxaban vs. warfarin for APS (RAPS) trial v Triple positive APA u ASTRO-APS (Apixiban for the secondary prevention of Thromboembolism Among Patients with APS) u Apixiban vs. warfarin u Clinical APS Raschi E. et al. Pharmacol Rev 2017;120:
26 Treatment of Arterial Thrombosis in APS WARRS trial compared ASA 325 mg to warfarin for ischemic stroke No difference in recurrent ischemic stroke or death Subgroup analysis of patients with APA N Engl J Med 2001 JAMA 2004
27 Recurrent Thrombosis while on Anticoagulation Approach to patients with recurrent thrombosis is not defined If you are on warfarin Can increase INR range to higher intensity Addition of antiplatelet therapy Change anticoagulation from warfarin to heparin/lmwh If you are on DOAC Change anticoagulation from DOAC to warfarin or LMWH
28 Case 3 A 31 year old woman with a history of SLE presents with painful fingertips Several days later, she develops focal neurologic findings and is found to have a stroke and her creatinine increased A skin biopsy shows microvascular thrombosis
29 Case 3 What are the treatment recommendations?
30 Catastrophic Antiphospholipid Antibody Syndrome (CAPS) Defined as thrombosis affecting 3 or more organs within a period of 1 week with histologic confirmation of small vessel thrombosis Occurs in <1% of patients with APL Mortality rate of 33 50%, most commonly due to cerebral and cardiac thrombosis or renal failure
31 Treatment for CAPS Treatment not standardized Combination of anticoagulation, corticosteroids, plasma exchange considered frontline Retrospective analysis of 250 patients from CAPS registry found highest rate of recovery (78%) achieved with this combination Rituximab for refractory/relapsed cases (or if anticoagulation contraindicated) Additional therapies may include IVIG, cyclophosphamide, eculizumab Cervera R. et al. Autoimmun Rev 2014;13:
DOACs in SPECIAL POPULATIONS
DOACs in SPECIAL POPULATIONS Ann K Wittkowsky PharmD, CACP, FASHP, FCCP Clinical Professor University of Washington School of Pharmacy Director, Anticoagulation Services UWMedicine Department of Pharmacy
More informationAll about Antiphospholipid Syndrome. M.B. Agarwal, MD Prof & Head, Dept of Haematology, Bombay Hospital Institute of Medical Sciences, Mumbai, India
All about Antiphospholipid Syndrome M.B. Agarwal, MD Prof & Head, Dept of Haematology, Bombay Hospital Institute of Medical Sciences, Mumbai, India 1 2 3 4 5 6 Antiphospholipid syndrome A study of 192
More informationUpdates in Diagnosis & Management of VTE
Updates in Diagnosis & Management of VTE TRACY MINICHIELLO, MD CHIEF, ANTICOAGULATION& THROMBOSIS SERVICE-SAN FRANCISCO VAMC PROFESSOR OF MEDICINE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO Financial Disclosures-NONE
More informationNew areas of development for the direct oral anticoagulants
New areas of development for the direct oral anticoagulants Varese March 2016 Disclosures for Harry R Büller Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Scientific Advisory
More informationSindrome da anticorpi antifosfolipidi: clinica e terapia. Vittorio Pengo Clinical Cardiology, Padova, Italy
Sindrome da anticorpi antifosfolipidi: clinica e terapia Vittorio Pengo Clinical Cardiology, Padova, Italy Revised Classification Criteria for the Antiphospholipid Syndrome J Thromb Haemost 2006;4:295-306
More informationDuration of Therapy for Venous Thromboembolism
Duration of Therapy for Venous Thromboembolism Michael B Streiff, MD FACP Associate Professor of Medicine and Pathology Medical Director, Johns Hopkins Anticoagulation Service Chairman, VTE Guideline Committee
More informationThrombophilia. Diagnosis and Management. Kevin P. Hubbard, DO, FACOI
Thrombophilia Diagnosis and Management Kevin P. Hubbard, DO, FACOI Clinical Professor of Medicine Kansas City University of Medicine and Biosciences-College of Osteopathic Medicine Kansas City, Missouri
More informationLa terapia del TEV nel paziente oncologico nell'era dei DOAC
XXVI CONGRESSO NAZIONALE FCSA Bologna, 5-7 Novembre 2015 Tromboembolismo venoso La terapia del TEV nel paziente oncologico nell'era dei DOAC ANNA FALANGA Immunoematologia e Medicina Trasfusionale e Centro
More informationDaniel Egan, MD April 13, 2012
Daniel Egan, MD April 13, 2012 Aug 2006 (at age 15): Acute unprovoked DVT in left common femoral vein Factor V Leiden heterozygous Positive lupus inhibitor Lovenox BID 2 weeks later: increased clot burden,
More informationThrombophilia. Stephan Moll, MD Medicine, Heme-Coag UNC Chapel Hill, NC. GASCO Atlanta Sept 8 th, Disclosures. Conflicts of interest: NONE
LA APLA 1 3 ACA Anti-ß2-GP I 2 45 Thrombophilia Stephan Moll, MD Medicine, Heme-Coag UNC Chapel Hill, NC GASCO Atlanta Sept 8 th, 2017 Disclosures Conflicts of interest: NONE Off-label product use discussion:
More informationThrombophilia: To test or not to test
Kenneth Bauer, MD Harvard Medical School, Boston, MA Professor of Medicine VA Boston Healthcare System Chief, Hematology Section Beth Israel Deaconess Medical Center, Boston, MA Director, Thrombosis Clinical
More informationWhat s new with DOACs? Defining place in therapy for edoxaban &
What s new with DOACs? Defining place in therapy for edoxaban & Use of DOACs in cardioversion Caitlin M. Gibson, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy University of North Texas
More informationDo s and Don t of DOACs DISCLOSURE
Do s and Don t of DOACs Tom DeLoughery, MD MACP FAWM Oregon Health and Sciences University DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau - None Consultant/Research none Content Expert: Elsevier
More informationthrombopoietin receptor agonists and University of Washington January 13, 2012
Tickle me eltrombopag: thrombopoietin receptor agonists and the regulation of platelet production Manoj Menon University of Washington January 13, 2012 Outline Clinical case Pathophysiology of ITP Therapeutic
More informationAnticoagulation Update: VTE Guidelines update, DOACs, procedural warfarin interruption, and icentra (whew!)
Anticoagulation Update: VTE Guidelines update, DOACs, procedural warfarin interruption, and icentra (whew!) Clinical Learning Day 2017 Scott C. Woller, MD Co-Director, Thrombosis Program Intermountain
More informationAre there still any valid indications for thrombophilia screening in DVT?
Carotid artery stenosis and risk of stroke Are there still any valid indications for thrombophilia screening in DVT? Armando Mansilha MD, PhD, FEBVS Faculty of Medicine of University of Porto Munich, 2016
More informationDuration of Anticoagulation? Peter Verhamme MD, PhD Department of Cardiovascular Medicine University of Leuven Belgium
Duration of Anticoagulation? Peter Verhamme MD, PhD Department of Cardiovascular Medicine University of Leuven Belgium Disclosures Honoraria and research support: Daiichi-Sankyo, Boehringer Ingelheim,
More informationAspirin as Venous Thromboprophylaxis
Canadian Society of Internal Medicine Nov 2, 2017 Aspirin as Venous Thromboprophylaxis Bill Geerts, MD, FRCPC Thromboembolism Consultant, Sunnybrook HSC Professor of Medicine, University of Toronto Disclosures
More informationFocus: l embolia polmonare Per quanto la terapia anticoagulante orale? Giulia Magnani 27 Gennaio, 2018
Focus: l embolia polmonare Per quanto la terapia anticoagulante orale? Giulia Magnani 27 Gennaio, 2018 NO DISCLOSURE Pulmonary Embolism Venous thromboembolism (VT) is the third most common cause of cardiovascular
More informationInteractive Case Vignette: DOACs (Direct Oral Anti-Coagulants) vs. Warfarin for APLA (Anti-Phospholipid Antibody Syndrome)
Interactive Case Vignette: DOACs (Direct Oral Anti-Coagulants) vs. Warfarin for APLA (Anti-Phospholipid Antibody Syndrome) Ara Metjian, MD Duke Debates Benign Hematologic Highlights April 22, 2017 Disclaimer
More informationManifestation of Antiphospholipid Syndrome among Saudi patients :examining the applicability of sapporo Criteria
Manifestation of Antiphospholipid Syndrome among Saudi patients :examining the applicability of sapporo Criteria Farjah H AlGahtani Associate professor,md,mph Leukemia,Lymphoma in adolescent,thromboembolic
More informationIndications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute
Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute Disclosures Research Support/P.I. Employee Leo Pharma
More informationVenous Thromboembolism (VTE) in Myeloma. Christine Chen May 2017
Venous Thromboembolism (VTE) in Myeloma Christine Chen May 2017 Objectives 1. Review the magnitude of the problem and why myeloma patients are at risk of VTE 2. Discuss thromboprophylaxis approaches in
More informationMedical Patients: A Population at Risk
Case Vignette A 68-year-old woman with obesity was admitted to the Medical Service with COPD and pneumonia and was treated with oral corticosteroids, bronchodilators, and antibiotics. She responded well
More informationChallenges in Anticoagulation and Thromboembolism
Challenges in Anticoagulation and Thromboembolism Ethan Cumbler M.D. Assistant Professor of Medicine Hospitalist Medicine Section University of Colorado Denver May 2010 No Conflicts of Interest Objectives
More informationMabel Labrada, MD Miami VA Medical Center
Mabel Labrada, MD Miami VA Medical Center *1-Treatment for acute DVT with underlying malignancy is for 3 months. *2-Treatment of provoked acute proximal DVT can be stopped after 3months of treatment and
More informationGenetic Tests for the Better Outcome of VTE? 서울대학교병원혈액종양내과윤성수
Genetic Tests for the Better Outcome of VTE? 서울대학교병원혈액종양내과윤성수 Thrombophilia A hereditary or acquired disorder predisposing to thrombosis Questions Why should we test? Who should we test For what disorders?
More informationDEEP VEIN THROMBOSIS (DVT): TREATMENT
DEEP VEIN THROMBOSIS (DVT): TREATMENT OBJECTIVE: To provide an evidence-based approach to treatment of patients presenting with deep vein thrombosis (DVT). BACKGROUND: An estimated 45,000 patients in Canada
More informationNew Antithrombotic Agents DISCLOSURE
New Antithrombotic Agents DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau None Research Alexion (PNH) delought@ohsu.edu Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University What
More informationAnticoagulation: Novel Agents
Anticoagulation: Novel Agents Scott C. Woller, MD Medical Director, Anticoagulation Management, Intermountain Healthcare Central Region, co-director Venous Thromboembolism Program, Intermountain Medical
More informationDVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE)
DVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE) Introduction VTE (DVT/PE) is an important complication in hospitalized patients Hospitalization for acute medical illness
More informationThromboembolism and cancer: New practices. Marc Carrier
Thromboembolism and cancer: New practices Marc Carrier Marc Carrier Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Honoraria Scientific Advisory Board Leo Pharma, BMS No relevant
More informationUPDATE ON TREATMENT OF ACUTE VENOUS THROMBOSIS
UPDATE ON TREATMENT OF ACUTE VENOUS THROMBOSIS Armando Mansilha MD, PhD, FEBVS 16 th National Congress of the Italian Society of Vascular and Endovascular Surgery Bologna, 2017 Disclosure I have the following
More informationAntiphospholipid antibodies
CARDIOLOGY PATIENT PAGE CARDIOLOGY PATIENT PAGE Antiphospholipid Antibodies Caron P. Misita, PharmD; Stephan Moll, MD Antiphospholipid antibodies (APLAs) are proteins that may be present in the blood and
More information10/24/2013. Heparin-Induced Thrombocytopenia (HIT) Anticoagulation Management in ECMO Therapy:
Anticoagulation Management in ECMO Therapy: Heparin-Induced (HIT) Michael H. Creer, MD Professor of Pathology Director, Clinical Laboratories, Medical Co- Director, Hematopathology and Chief, Division
More informationAnticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging
Anticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging Scott C. Woller, MD Co-Director, Thrombosis Program Intermountain Medical
More informationChallenges in Anticoagulation Bridging and Emerging Therapies. Disclosures and Relationships. Objectives. Dr. Cumbler has no conflicts of interest
Challenges in Anticoagulation Bridging and Emerging Therapies Ethan Cumbler MD FACP Associate Professor of Medicine Hospitalist Medicine Section University of Colorado Denver 2011 Disclosures and Relationships
More informationDuration of Anticoagulant Therapy. Linda R. Kelly PharmD, PhC, CACP September 17, 2016
Duration of Anticoagulant Therapy Linda R. Kelly PharmD, PhC, CACP September 17, 2016 Conflicts of Interest No conflicts of interest to report Objectives At the end of the program participants will be
More informationAPPENDIX 2 Eight New Cases of LAHS and Review of Literature: Treatment and Follow-Up
Supplementary Digital Content 2 Mazodier Lupus Anticoagulant- Hypoprothrombinemia Syndrome: Report of 8 Cases and Review of the Literature Medicine (Baltimore). 2012;91(5). APPEIX 2 Eight New Cases of
More informationFACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS
New Horizons In Atherothrombosis Treatment 2012 순환기춘계학술대회 FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS Division of Cardiology, Jeonbuk National University Medical School Jei Keon Chae,
More informationVenous thrombosis in unusual sites
Venous thrombosis in unusual sites Walter Ageno Department of Medicine and Surgery University of Insubria Varese Italy Disclosures Employment Research support Scientific advisory board Consultancy Speakers
More informationClinical issues which drug for which patient
Anticoagulants - a matter of heart! Towards a bright future? Clinical issues which drug for which patient Sabine Eichinger Dept. of Medicine I Medical University of Vienna/Austria Conflicts of interest
More informationManagement of Cancer Associated VTE
Management of Cancer Associated VTE Jean M. Connors, MD 2017 Master Class Course Anticoagulation Management Services BWH/DFCI Hemostatic Antithrombotic Stewardship BWH Assistant Professor of Medicine HMS
More informationPerioperative Management of the Anticoagulated Patient
Perioperative Management of the Anticoagulated Patient Citywide Resident Perioperative Medical Consultation Conference 5/5/17 Matthew Eisen, MD Director, Anticoagulation Services MetroHealth Medical Center
More informationApproach to Thrombosis
Approach to Thrombosis Theera Ruchutrakool, M.D. Division of Hematology Department of Medicine Siriraj Hospital Faculty of Medicine Mahidol University Approach to Thrombosis Thrombosis: thrombus formation
More informationDiagnosis and Management of Immune Thrombocytopenias. Thomas L. Ortel, M.D., Ph.D. Duke University Medical Center 2 November 2016
Diagnosis and Management of Immune Thrombocytopenias Thomas L. Ortel, M.D., Ph.D. Duke University Medical Center 2 November 2016 Disclosures Research support: NIH, CDC, Eisai, Pfizer, Daiichi Sankyo, GlaxoSmithKline,
More informationCADTH Rapid Response Report: ASA for Venous Thromboembolism Prophylaxis: Evidence for Clinical Benefit and Harm
CADTH Rapid Response Report: ASA for Venous Thromboembolism Prophylaxis: Evidence for Clinical Benefit and Harm P. Timothy Pollak, MD, PhD University of Calgary Rocky Mountain/ACP Internal Medicine Meeting,
More informationWarfarin for Long-Term Anticoagulation. Disadvantages of Warfarin. Narrow Therapeutic Window. Warfarin vs. NOACs. Challenges Monitoring Warfarin
1 2:15 pm The Era of : Selecting the Best Approach to Treatment SPEAKER Gregory Piazza, MD, MS Presenter Disclosure Information The following relationships exist related to this presentation: Gregory Piazza,
More informationUnderstanding Best Practices in Anticoagulation Therapy in Patients with Venous Thromboembolism. Rajat Deo, MD, MTR
Understanding Best Practices in Anticoagulation Therapy in Patients with Venous Thromboembolism Rajat Deo, MD, MTR Director of Translational Research in Cardiac Arrhythmias Division of Cardiovascular Medicine
More informationThe clinical relevance of AMPLIFY programme
Venice October 16th 2015 The clinical relevance of AMPLIFY programme Francesco Dentali Department of Clinical Medicine Insubria University Varese Disclosures Bayer Bristol-Myers Squibb/Pfizer Boehringer
More informationDISCLOSURE. What I am Talking About. Rational Use of Antiplatelet Agents. Aspirin. Tom DeLoughery, MD MACP FAWM
Rational Use of Antiplatelet Agents DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau None Tom DeLoughery, MD MACP FAWM Oregon Health and Sciences University What I am Talking About 1. Current
More informationJoshua D. Lenchus, DO, RPh, FACP, SFHM Associate Professor of Medicine and Anesthesiology University of Miami Miller School of Medicine
Joshua D. Lenchus, DO, RPh, FACP, SFHM Associate Professor of Medicine and Anesthesiology University of Miami Miller School of Medicine Antithrombotics Antiplatelets Aspirin Ticlopidine Prasugrel Dipyridamole
More informationObesity, renal failure, HIT: which anticoagulant to use?
Obesity, renal failure, HIT: which anticoagulant to use? Mark Crowther with thanks to Dr David Garcia and others. This Photo by Unknown Author is licensed under CC BY-SA 1 2 Drug choices The DOACs have
More informationNew Antithrombotic Agents
New Antithrombotic Agents Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau None What I am Talking About 1. New Antithrombotic
More informationASH 2011: Clinically Relevant Highlights Regarding Venous Thromboembolism and Anticoagulation
ASH 2011: Clinically Relevant Highlights Regarding Venous Thromboembolism and Anticoagulation Stephan Moll Department of Medicine, Division of Hematology-Oncology, University of North Carolina School of
More informationUsing DOACs in CAD Patients in Sinus Ryhthm Results of the ATLAS ACS 2, COMPASS and COMMANDER-HF Trials
Using DOACs in CAD Patients in Sinus Ryhthm Results of the ATLAS ACS 2, COMPASS and COMMANDER-HF Trials 19 th Annual San Diego Heart Failure Symposium for Primary Care Physicians January 11-12, 2019 La
More informationDOACs in CAT. Fellow: Shweta Jain, MD Faculty Discussant: David Garcia, MD
DOACs in CAT Fellow: Shweta Jain, MD Faculty Discussant: David Garcia, MD Case 65 year old post menopausal female Left breast lesion Oct 2015 Biopsy Invasive ductal carcinoma Lumpectomy with SNB- pt1cno
More informationIs Oral Rivaroxaban Safe and Effective in the Treatment of Patients with Symptomatic DVT?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 1-1-2013 Is Oral Rivaroxaban Safe and Effective
More informationSecond line therapy for ITP should be TPO agonists. Nichola Cooper Imperial Health Care NHS Trust
Second line therapy for ITP should be TPO agonists Nichola Cooper Imperial Health Care NHS Trust COHEM 2012 Antiplatelet antibodies Platelet count after infusion with patient plasma Hours Days T cells
More informationNew Anticoagulants Therapies
New Anticoagulants Therapies Rachel P. Rosovsky, MD, MPH October 22, 2015 Conflicts of Interest No disclosures 2 Agenda 3 Historical perspective Novel oral anticoagulants Stats Trials Approval Concerns/Limitations
More informationDirect Oral Anticoagulants Beyond Atrial Fibrillation and Venous thrombosis
Direct Oral Anticoagulants Beyond Atrial Fibrillation and Venous thrombosis Robert D. McBane II Gonda Vascular Center 2018 MFMER 3755772-1 Disclosures Bristol-Myers Squibb Research Grant Apixaban in Cancer
More informationUpdate on the Management of Cancer Associated VTE
Update on the Management of Cancer Associated VTE Jean M. Connors, MD 2018 Master Class Course Anticoagulation Management Services BWH/DFCI Hemostatic Antithrombotic Stewardship BWH Associate Professor
More informationTHROMBOTIC DISORDERS: The Final Frontier
THROMBOTIC DISORDERS: The Final Frontier Jeffrey I. Weitz, MD, FRCP(C), FACP Professor of Medicine and Biochemistry McMaster University Canada Research Chair in Thrombosis Heart & Stroke Foundation/ J.F.
More informationCurrent View of the Treatment of Antiphospholipid Syndrome
GROUPE HOSPITALIER PITIE SALPETRIERE Current View of the Treatment of Antiphospholipid Syndrome Pr Zahir AMOURA Department of Internal Medicine French National Reference center for SLE and APS Hôpital
More informationUpdates in Coagulation Thrombophilia testing and direct oral anticoagulants. Kevin Y. Chen, MD Hematology and Medical Oncology October 13, 2017
Updates in Coagulation Thrombophilia testing and direct oral anticoagulants Kevin Y. Chen, MD Hematology and Medical Oncology October 13, 2017 No conflicts of interest Introduction to thrombosis Hemostasis
More informationPractical Considerations for Using Oral Anticoagulants in Patients with Chronic Kidney Disease
Practical Considerations for Using Oral Anticoagulants in Patients with Chronic Kidney Disease Cyrille K. Cornelio, Pharm.D. PGY2 Cardiology Pharmacy Resident The University of Oklahoma College of Pharmacy
More informationOral rivaroxaban versus standard therapy for the acute and continued treatment of symptomatic deep vein thrombosis. The EINSTEIN DVT study.
Oral rivaroxaban versus standard therapy for the acute and continued treatment of symptomatic deep vein thrombosis. The EINSTEIN DVT study Comments Harald Darius, Berlin Disclosures for Harald Darius Research
More information3/19/2012. What is the indication for anticoagulation? Has the patient previously been on warfarin? If so, what % of the time was the INR therapeutic?
Abigail E. Miller, PharmD, BCPS Clinical Specialist, Cardiology University of North Carolina Hospitals I have no personal financial relationships with the manufacturers of the products to disclose. Boehringer
More informationThrombophilias: A Practical Approach
Disclosures Thrombophilias: A Practical Approach Speaker s Bureau: BMS/Pfizer (Apixaban) PI Altru Health System: EVE Trial Apixaban in Malignancy Keith E Swanson MD North Dakota Family Medicine Conference,
More informationPulmonary embolism: Acute management. Cecilia Becattini University of Perugia, Italy
Pulmonary embolism: Acute management Cecilia Becattini University of Perugia, Italy Acute pulmonary embolism: Acute management Diagnosis Risk stratification Treatment Non-high risk PE: diagnosis 3-mo VTE
More informationManagement of Patients with Atrial Fibrillation and Stents: Is Three Drugs Too Many?
Management of Patients with Atrial Fibrillation and Stents: Is Three Drugs Too Many? Neal S. Kleiman, MD Houston Methodist DeBakey Heart and Vascular Center, Houston, TX Some Things Are Really Clear 2013
More informationCase Presentation. A Case from the Clinic. Additional Data. Examination and Data 10/27/2013
Northwestern University Feinberg School of Medicine Treatment of Severe Thrombocytopenia in Systemic Lupus Erythematosus: The Role of New Agents Disclosures: Advisory Board: Incyte Corporation Speaker
More informationROLE OF LOW MOLECULAR WEIGHT HEPARIN IN THE AGE OF DIRECT ORAL ANTICOAGULANTS
ROLE OF LOW MOLECULAR WEIGHT HEPARIN IN THE AGE OF DIRECT ORAL ANTICOAGULANTS Chee Yen Lin Consultant Haematologist NCIS Haematology National University Hospital Singapore Nomenclature direct oral anticoagulant
More informationMost Common Hemostasis Consults: Thrombocytopenia
Most Common Hemostasis Consults: Thrombocytopenia Cindy Neunert, MS MSCS Assistant Professor, Pediatrics CUMC Columbia University TSHNA Meeting, April 15, 2016 Financial Disclosures No relevant financial
More informationVascular Protection: Preventing Thrombotic Complications of VTE and PAD
Vascular Protection: Preventing Thrombotic Complications of VTE and PAD Thursday, October 11, 2018, 2:00pm ET Guest Speakers: Geoff Barnes, MD Scott Damrauer, MD Moderators: Tracy Minichiello, MD; Sara
More informationHow to prevent thrombotic diseases? Sergio Fusco, MD
How to prevent thrombotic diseases? Sergio Fusco, MD Geriatric Division - Department of Internal Medicine Ospedale Dell'Angelo - Venice, Italy CONFLICT OF INTEREST DISCLOSURE I have no potential conflict
More informationUpdates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism
Disclosures Updates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism No financial conflicts of interest Member of the ABIM Focused- Practice in Hospital Medicine Self Examination Process
More informationNew Oral Anticoagulants Prevention and Treatment of DVT and PE
New Oral Anticoagulants Prevention and Treatment of DVT and PE Grigoris T Gerotziafas Groupe de Thrombose Equipe de recherche ER2UPMC Interactions cellulaires tumorales et leur environnement et réponses
More informationDental Management Considerations for Patients on Antithrombotic Therapy
Dental Management Considerations for Patients on Antithrombotic Therapy Warfarin and Antiplatelet Joel J. Napeñas DDS FDSRCS(Ed) Program Director General Practice Residency Program Department of Oral Medicine
More informationCancer Associated Thrombosis An update.
Cancer Associated Thrombosis An update. Simon Noble Marie Curie Professor of Supportive and Palliative Medicine Marie Curie Palliative Care Research Centre Cardiff University The coagulation pathway LIQUID
More informationEvolution of clinical guidelines for ITP: Role of Romiplostim
Slovenian Haematological Society 16 April 2010, Podčetrtek Evolution of clinical guidelines for ITP: Role of Romiplostim Dr. Roberto Stasi Department of Haematology St George's Hospital London Is there
More informationObjectives. Venous Thromboembolism (VTE) Prophylaxis. Case VTE WHY DO IT? Question: Who Is At Risk?
Objectives Venous Thromboembolism (VTE) Prophylaxis Rishi Garg, MD Department of Medicine Identify patients at risk for VTE Options for VTE prophylaxis Current Recommendations (based on The Seventh ACCP
More informationChoosing and Managing Direct Oral Anticoagulants (DOACs)
Choosing and Managing Direct Oral Anticoagulants (DOACs) Ana G. Antun, MD, MSc Assistant Professor, Department of Hematology and Medical Oncology Winship Cancer Institute of Emory University 1 Outline
More informationJoost van Veen Consultant Haematologist
Joost van Veen Consultant Haematologist Bridging anticoagulation - conclusion Aim Questions What is the evidence? Does oral anticoagulation need to be stopped and if so when? When and at what dose is alternative
More informationUpdates in venous thromboembolism. Cecilia Becattini University of Perugia
Updates in venous thromboembolism Cecilia Becattini University of Perugia News for VTE Diagnosis Treatment the acute phase the agents Pulmonary embolism: diagnosis Vein ultrasonography Meta-analysis 15
More informationDirect oral anticoagulants to prevent VTE recurrence: full or reduced dosage? MA Sevestre CHU Amiens
Direct oral anticoagulants to prevent VTE recurrence: full or reduced dosage? MA Sevestre CHU Amiens Faculty disclosure Marie Antoinette Sevestre I disclose the following financial relationships: Paid
More informationPrevention and management of venous thromboembolism M. AAPRO
Prevention and management of venous thromboembolism M. AAPRO Thromboprophylaxisof DVT and PE in AmbulatoryCancerPatients Zurich, February 2017 M. AAPRO Based on a lesson in April 2016 by M. DICATO M.D.,
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC DEBATE: DOAC vs Good Old Warfarin André Roussin MD, FRCP, CSPQ CHUM and ICM/MHI Associate professor University of Montreal A. Roussin
More informationNew Oral Anticoagulant Drugs in the Prevention of DVT
New Oral Anticoagulant Drugs in the Prevention of DVT Targets for Anticoagulants ORAL DIRECT VKAs inhibit the hepatic synthesis of several coagulation factors Rivaroxaban Apixaban Edoxaban Betrixaban X
More informationDVT Pathophysiology and Prophylaxis in Medically Hospitalized Patients. David Liff MD Oklahoma Heart Institute Vascular Center
DVT Pathophysiology and Prophylaxis in Medically Hospitalized Patients David Liff MD Oklahoma Heart Institute Vascular Center Overview Pathophysiology of DVT Epidemiology and risk factors for DVT in the
More informationNew oral anticoagulants and Palliative Care.
New oral anticoagulants and Palliative Care. Simon Noble Marie Curie Professor of Supportive and Palliative Medicine Marie Curie Palliative Care Research Centre Cardiff University The coagulation pathway
More informationClinical Controversies in Perioperative Medicine
Update on Perioperative Medicine Clinical Controversies in Perioperative Medicine Hugo Quinny Cheng, MD Division of Hospital Medicine University of California, San Francisco Cardiac Medications & Perioperative
More informationDisclosures. DVT: Diagnosis and Treatment. Questions To Ask. Dr. Susanna Shin - DVT: Diagnosis and Treatment. Acute Venous Thromboembolism (VTE) None
Disclosures DVT: Diagnosis and Treatment None Susanna Shin, MD, FACS Assistant Professor University of Washington Acute Venous Thromboembolism (VTE) Deep Venous Thrombosis (DVT) Pulmonary Embolism (PE)
More informationLessons from recent antithrombotic studies and trials in atrial fibrillation
Lessons from recent antithrombotic studies and trials in atrial fibrillation Thromboembolism cause of stroke in AF Lars Wallentin Uppsala Clinical Research Centre (UCR) Uppsala Disclosures for Lars Wallentin
More informationEdoxaban. Direct Xa inhibitor Direct thrombin inhibitor Direct Xa inhibitor Direct Xa inhibitor
This table provides a summary of the pharmacotherapeutic properties, side effects, drug interactions and other important information on the four anticoagulant medications currently in use or under review
More informationHEPARIN-INDUCED THROMBOCYTOPENIA (HIT)
HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) OBJECTIVE: To assist clinicians with the investigation and management of suspected and documented heparin-induced thrombocytopenia (HIT). BACKGROUND: HIT is a transient,
More informationAntiphospholipid Syndrome: It s Far More Than You Think
Antiphospholipid Syndrome: It s Far More Than You Think Richard Furie, MD Chief, Division of Rheumatology Northwell Health Professor of Medicine Zucker School of Medicine at Hofstra/Northwell Richard Furie,
More informationDirect Oral Anticoagulants (DOACs). Dr GM Benson Director NI Haemophilia Comprehensive Care Centre and Thrombosis Unit BHSCT
Direct Oral Anticoagulants (DOACs). Dr GM Benson Director NI Haemophilia Comprehensive Care Centre and Thrombosis Unit BHSCT OAC WARFARIN Gold standard DABIGATRAN RIVAROXABAN APIXABAN EDOXABAN BETRIXABAN
More informationAnticoagulation Update: DOACs, VTE Guidelines, Bridging and icentra
Anticoagulation Update: DOACs, VTE Guidelines, Bridging and icentra (whew!) Scott C. Woller, MD Co Director, Thrombosis Program Intermountain Medical Center Professor of Medicine University of Utah School
More informationLupus Anticoagulants (LA), Antiphospholipid (APL) Antibodies & APL Syndrome: Review & Update. Antiphospholipid. Antiphospholipid
, Antiphospholipid (APL) Antibodies & APL Syndrome: Review & Update William L. Nichols, MD Mayo Clinic College of Medicine Rochester, Minnesota USA Disclosures & Objectives (Nichols) Disclosures Relevant
More information